Uncategorized

Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced the completion of patient enrollment for the China open-label extension of the Phase 3 NefIgArd study.

Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study Read More »

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – August 01, 2023

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 19 individuals hired by Sarepta in July 2023.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – August 01, 2023 Read More »

Scroll to Top